Physician profile
Thomas Carter
NPI 1649464439
$772.90
in general payments reported to CMS, 2019-2025
20 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $39.95 · 2024: $520 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $111.06 | 2024-2025 | |
| Lilly USA, LLC | $74.96 | 2024 | Mounjaro |
| Novo Nordisk INC | $64.95 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $59.47 | 2023-2024 | Otezla, Repatha, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $54.57 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.61 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $48.70 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $45.94 | 2024-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Inspire Medical Systems, INC. | $38.96 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.75 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $25.45 | 2025 | Shingrix, Arexvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.55 | 2024 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $23.73 | 2024 | |
| Janssen Pharmaceuticals, INC | $22.53 | 2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.57 | 2024 | Xifaxan |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $18.28 | 2024 | Aristada, Lybalvi |
| Seqirus USA INC | $15.66 | 2024 | Fluad, Flucelvax |
| Depuy Synthes Sales INC. | $14.32 | 2024 | Monovisc, Orthovisc |
| Axsome Therapeutics, INC. | $14.29 | 2025 | Auvelity |
| Aimmune Therapeutics, INC. | $13.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.